EU Joint Action on Rare Cancers (JARC)

The framework for EU stakeholders and policy makers to work together, set the agenda at national level and help provide diagnostics, healthcare and support to all our citizens who suffer from rare cancer.

The Joint Action on Rare Cancers is a multistakeholders collaboration between 18 Member States and European Commission.

Joint Action on Rare Cancers 

OBJECTIVES

Improving epidemiological surveillance of rare in the EU
Identifying standards of care for all falilies of rare cancers to ensure sharing of best practices and equality of care for rare cancers accross Europe, particulary through clinical networking
Improving the implementation at local level and within ERNs of clinical practice guidelines on rare cancers
Promoting integration of translational research innovations into rare cancer care
Improving education on rare cancers for medical and non medical experts to ameliorate management of rare cancers and to improve rare cancer patients empowerment in the EU
Identifying core strategies to incorporate in national cancer plans and rare disease plans to address the specific needs of rare cancers accross EU 

Tasks of work package 6

  • Map available clinical practice guidelines (CPGs) at the European level on all families of rare cancers and identify gaps

  • Quality evaluation of existing guidelines for rare cancer subtypes  

The JARC Work Package 6 maintains this website to share the results of quality evaluation of existing CPGs at European local and national level on rare cancers with partners involved in the EU JARC Project. However, the JARC Work Package 6 does not accept any responsibility or obligation of any kind whatsoever with regard to the information contained on this site.

The  JARC WP 6 Website contains links to other websites.

Not having control over the content of these third-party websites, no responsibility is assumed for their policies or practices.

Therefore, please review the privacy policies of these third-party websites.

Tasks of work package 6

  • Open issues about implementation of CPGs at the local level and their interface with reimbursement systems

  • Work out solutions on how to assess the implementation of CPGs in the context of ERNs and national clinical collaborative networks

This site was designed with the
.com
website builder. Create your website today.
Start Now